

Appendix 4E – Preliminary Final Report

(ASX Listing rule 4.3A)

Company Name:	Emefcy Group Limited (the 'Company') (formerly Savcor Group Limited)
ABN:	52 127 734 196
Reporting Period:	Financial year ended 31 December 2015
Previous Reporting Period:	Financial year ended 31 December 2014

Results for Announcement to the Market

The results of Emefcy Limited for the year ended 31 December 2015 are as follows:

				2015 (US\$)		2014 (US\$)
Revenues from ordinary activities	Decrease	-98%	to	1,179	from	60,000
Loss after tax attributable to members	Increase	350%	to	(9,088,501)	from	(2,020,000)
Net loss for the period attributable to members	Increase	350%	to	(9,088,501)	from	(2,020,000)

Brief explanation of figures reported above

The consolidated loss for the Company after income tax for the reporting period was US\$ 9,088,501 (2014: loss of US\$ 2,020,000). This figure includes the non-cash costs associated with the reverse takeover of Emefcy Group Limited of US\$6,801,624 and cash costs of US\$1m related to the same. There is no tax payable or refund due during the current reporting period (2014: Nil).

The results also reflect 13 days for Emefcy Group Limited in 2015 and the full year operating losses for Emefcy Limited (Israel) in 2015 and 2014.

For further details relating to the current period's results, refer to the Operations Report contained within this document.

Dividends

No dividends have been paid or declared by the Company since the beginning of the current reporting period. No dividends were paid for the previous reporting period.

Net Tangible Assets

	Consolidated Entity	
	31 December 2015	31 December 2014
	US\$	US\$
Net Tangible Assets	7,075,179	1,828,000
Shares (No.)	177,437,410	65,000,000 ¹
Net Tangible Assets per security	0.04	0.03

Loss per Share

	Consolidated Entity	
	31 December 2015	31 December 2014
	US\$	US\$
Basic loss per share	(0.08)	(0.03)
Diluted loss per share	(0.08)	(0.03)

Status of Audit of Accounts

These accounts are currently in the process of being audited. An Annual Report for the year ended 31 December 2015 containing the Audit Report shall be provided in due course.

¹ The number of shares has been revised and reflects the actual shares of Emefcy Limited (Israel) (the legal parent) in issue after the date of acquisition.



ABN 52 127 734 196

Appendix 4E

Preliminary Final Report

For the Year Ended 31 December 2015

In Compliance with ASX Listing Rule 4.3A

(Formerly Savcor Group Limited)

Table of Contents

Review of Operations 4

Financial Report

 Statement of Profit or Loss and Other Comprehensive Income 7

 Statement of Financial Position 8

 Statement of Changes in Equity 9

 Statement of Cash Flows 10

 Notes to the Financial Statements 11

Corporate Directory 17

Review of Operations

The Directors of Emefcy Group Limited (“Emefcy” or “the Company”) provide the following Report in relation to the Company for the year ended 31 December 2015.

Acquisition of Emefcy Limited (Israel)

In the first half of the 2015 year, the former Savcor Directors targeted global opportunities in environmentally clean technologies. This broader industry has a number of strong market drivers including a growing global population, finite natural resources and in many countries, government legislated carbon reduction requirements. All of these factors combine into an industry anticipated to create persistent, increasing demand and need for new innovative solutions.

A number of innovative companies with potential opportunities were evaluated. Two companies in the water technology segment were shortlisted for detailed due diligence. Emefcy, an award-winning Israeli company with advanced energy efficient wastewater treatment solutions became the primary candidate for acquisition.

On 20 July 2015, the Company entered into a binding Term Sheet, subject to certain conditions, with the Vendors of Emefcy Limited – a company incorporated and operating in Israel.

The Company completed the acquisition of Emefcy Limited (Israel) and changed its name from Savcor Group Limited to Emefcy Group Limited on 18 December 2015.

The consideration for the acquisition was the issue of 65,000,000 fully paid ordinary shares to Vendors. In addition, the Vendors are eligible to be issued a further total of 45,000,000 shares on the satisfaction of each of two commercial milestones (22,500,000 shares per milestone). One Vendor received US\$1 million on completion in lieu of receiving shares plus a non-convertible interest free note giving them a further entitlement to a further maximum of US\$2 million on the satisfaction of each of the same two commercial milestones (US\$ 1 million per milestone).

As the first milestone is considered to be virtually assured of being satisfied, the additional US\$1 million consideration payable to one Vendor has been taken into account in the reported results. It should be noted however that the actual cash payment is not due until the earlier of 18 June 2018 or a subsequent capital raising being successfully completed.

In support of the acquisition, the Company exceeded its minimum offering target and raised approximately US\$ 9.8million (AU\$ 13.8 million) through a public offering of shares at AU\$0.20 cents in the company in December 2015.

Through the acquisition, the Vendor shareholders of Emefcy Limited have the potential, subject to satisfaction of milestones, to own a majority of the issued capital of the Company. Consequently the principles of reverse acquisition accounting apply in the presentation of financial results, as if Emefcy Limited acquired Emefcy Group Limited.

The financial results for the year ended 31 December 2015 reflect the results of Emefcy Group Limited (formerly Savcor Group Limited) for the thirteen days from 18 December 2015 (date of acquisition) to 31 December 2015, and the full operating losses of Emefcy Limited (Israel) in 2015 and 2014.

The directors of Emefcy have adopted US dollars as the most appropriate presentation currency.

Principal Activities

Emefcy Limited's principal activities in the course of the financial year were the research, development and commercialisation of innovative wastewater treatment systems: incorporating Spiral Aerobic Biofilm Reactor ("SABRE") and Electrogenic Bio Reactor ("EBR") technologies, for use in decentralised settings.

The acquisition of Emefcy Group Limited took effect as of 18 December 2015.

Other than the above, there were no other significant changes in the nature of the Company's principal activities during the financial year.

The consolidated loss for the Company after income tax for the reporting period was US\$ 9,088,501 (2014: loss of US\$ 2,020,000). This figure includes the non-cash costs associated with the reverse takeover of Emefcy Group Limited of US\$6,801,624 and cash costs of US\$1m related to the same.

Operations

SABRE "Spiral Aerobic Biofilm Reactor" is a modular decentralised wastewater treatment solution offering a number of significant advantages compared to traditional wastewater treatment technologies, including:

- Relatively low capital cost;
- An estimated 90% saving on energy costs;
- Decentralised system ideal for neighbourhood, resort, remote or off-grid locations;
- Modular in construction and readily expandable; and
- Lower maintenance.

Future generation SABRE2 and SUBRE are higher capacity solutions being developed for broader markets. The Electrogenic Bio Reactor (EBR) system is an innovative solution for wastewater treatment, based on microbial fuel cell technology. It enables direct electricity generation from wastewater thereby removing biological contamination and treating the wastewater.

Following twelve months of successful field trials, in the December quarter 2015, Emefcy Limited (Israel) achieved the first commercial sale of the SABRE technology to the Ha-Yogev municipality in Israel with revenues anticipated from the project commencing in the first quarter of 2016.

Ha-Yogev is a rural community surrounded by agricultural fields in the valley of Jezreel, Israel. Its extensive wastewater treatment plant receives combined domestic and cowshed wastewater, and the effluent is intended for irrigation nearby. However, due to high load coming from the cowshed, ammonium concentration in treated water is far above allowed limits.

Emefcy was selected and has completed building SABRE modules for a commercial-scale plant which improves the quality of the treated water by implementing its patented SABRE technology to remove excess ammonia to comply with local requirements. Projected size of this phase of the project is approximately US\$576k of which the expected revenue for Emefcy is US\$274k in 2016. The installation of the modules is imminent.

Once the plant is fully operational this will be a very important proof point of the viability of Emefcy's SABRE technology for municipalities, agricultural communities, and wastewater reuse.

Emefcy's future technology under development, EBR - The Electrogenic Bioreactor will harvest electricity from highly-loaded industrial wastewater that is typically very costly to treat. The energy's value has the potential to completely offset other treatment operating costs.

In addition to exploring entry strategies into other large markets, particularly the very large Chinese market, Emefcy is also refining its "water as a service" model which has the potential to turn the Company into a mini-utility, with annuity-type income streams.

Summary

The Company has been reinvigorated through the acquisition of Emefcy Limited and its awarded wastewater treatment technology and team with the experience and credentials to deliver this technology to global markets. The newly established Board of Directors is highly experienced in the commercialisation of world class technology and comprises Richard Irving Executive Chairman, Eytan Levy Managing Director & CEO, Ross Haghighat Non-Executive Director, Peter Marks Non-Executive Director, and Phillip Hains Non-Executive Director and Joint Company Secretary.

The Company's stated vision is:

To become the market leader for resource-efficient & energy-positive wastewater treatment within our target segments in municipal & industrial wastewater by 2020, a market estimated at over US\$5.7 billion.

The Company's goals for 2016 towards achieving the five year vision are clearly defined and include revenue, sales, product and market goals; details of which are available on the Company's website www.emefcy.com.

This report is made in accordance with a resolution of Directors.

Mr Richard Irving
Executive Chairman
Melbourne
29 February 2016

Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 31 December 2015

Consolidated	Notes	31 December 2015 US\$	31 December 2014 US\$
Revenues			
Interest Revenue	3	1,179	60,000
Expenses			
Administration expenses		(544,030)	(537,000)
Corporate consulting fees		(99,700)	-
Travel expense		(9,608)	-
Director expense		(90,622)	-
Finance costs		(32,520)	(232,000)
Legal expenses		(76,422)	-
Amortisation and depreciation		(70,922)	(26,000)
Research and development expenses		-	(1,213,000)
Sales and marketing expenses		(125,705)	(72,000)
Foreign exchange gain/(loss)		(238,517)	-
Listing expense recognised on reverse acquisition ¹		(5,801,624)	-
Cash and deferred considerations of acquisition ²		(2,000,000)	-
Loss before income tax expense		(9,088,501)	(2,020,000)
Income tax expense		-	-
Loss after income tax expense from continuing operations		(9,088,501)	(2,020,000)
Loss after income tax expense for the year attributable to the owners of Emefcy Group Limited		(9,088,501)	(2,020,000)
Other comprehensive income:			
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translating foreign operations		226,173	-
Other comprehensive losses for the period, net of tax		226,173	-
Total comprehensive loss for the period attributable to the owners of Emefcy Group Limited		(8,862,328)	(2,020,000)
Losses per share for loss attributable to the owners of Emefcy Group Limited			
Basic loss per share	5	(0.08)	(0.03)
Diluted loss per share	5	(0.08)	(0.03)

¹ The listing expense was recognised on the reverse acquisition of Emefcy Group Limited. It was a non-cash expense and has no effect on the Company's cash reserve.

² This consists of US\$1m cash payment made to Emefcy's vendor on completion of the acquisition and US\$1m non-current redeemable note payable to Emefcy's vendor upon satisfaction of the milestone pursuant to the acquisition agreement.

The accompanying notes form part of these financial statements.

Statement of Financial Position

As at 31 December 2015

Consolidated	Notes	31 December 2015 US\$	31 December 2014 US\$
Current Assets			
Cash and cash equivalents		8,478,927	1,617,000
Restricted cash		32,127	34,000
Trade and other receivables		204,206	194,000
Inventories		194,969	-
Prepayments		68,137	-
Total current assets		8,978,366	1,845,000
Non-Current Assets			
Trade and other receivables		2,357	7,000
Property, plant and equipment		823,720	898,000
Intangible assets		2,286,877	575,000
Total non-current assets		3,112,954	1,480,000
TOTAL ASSETS		12,091,320	3,325,000
Current Liabilities			
Trade and other payables		617,519	327,000
Total current liabilities		617,519	327,000
Non-Current Liabilities			
Trade and other payables		1,111,745	595,000
Other liabilities		1,000,000	-
Total non-current liabilities		2,111,745	595,000
TOTAL LIABILITIES		2,729,264	922,000
NET ASSETS		9,362,056	2,403,000
Equity			
Contributed equity	6	28,481,775	12,660,392
Reserve		226,173	-
Accumulated losses		(19,345,892)	(10,257,392)
TOTAL EQUITY		9,362,056	2,403,000

The accompanying notes form part of these financial statements.

Statement of Changes in Equity

For the Year Ended 31 December 2015

Consolidated	Note	Contributed Equity US\$	Foreign Currency Reserves \$USD	Accumulated Losses US\$	Total US\$
Balance as at 31 December 2013		12,649,392	-	(8,237,392)	4,412,000
Loss for the period attributable to members of the parent entity		-	-	(2,020,000)	(2,020,000)
Total comprehensive income for the period		-	-	(2,020,000)	(2,020,000)
<i>Transactions with owners in their capacity as owners</i>					
Contributions of equity		11,000	-	-	11,000
Balance as at 31 December 2014		12,660,392	-	(10,257,392)	2,403,000
Loss for the period attributable to members of the parent entity		-	-	(9,088,501)	(9,088,501)
Other comprehensive income/(expense) for the period		-	226,173	-	226,173
Total comprehensive income for the period		-	226,173	(9,088,501)	(8,862,328)
<i>Transactions with owners in their capacity as owners</i>					
Contributions of equity	6	15,821,383	-	-	15,821,383
Balance as at 31 December 2015		28,481,775	226,173	(19,345,893)	9,362,055

The accompanying notes form part of these financial statements.

Statement of Cash Flows

For the Year Ended 31 December 2015

Consolidated	31 December 2015 US\$	31 December 2014 US\$
<i>Cash flows from operating activities</i>		
Payments to suppliers	(518,822)	(1,681,000)
Interest received	1,179	
Net cash flows (used in)/provided by operating activities	(517,642)	(1,681,000)
<i>Cash flows related to investing activities</i>		
Payment for purchases of plant and equipment	(5,628)	(212,000)
Refund (Payment) of long term lease deposits	4,812	(4,000)
Payment for restricted cash	-	(18,000)
Cash consideration of acquisition	(1,000,000)	-
Proceeds from sale of marketable securities, net	-	2,113,000
Capitalisation of research and development expenses	(1,221,648)	(667,000)
Net cash flows (used in)/provided by investing activities	(2,222,466)	1,212,000
<i>Cash flows related to financing activities</i>		
Proceeds from issues of securities	10,634,077	-
Capital raising costs	(1,062,534)	-
Grants from governmental institutions	-	248,000
Net cash flows (used in)/provided by financing activities	9,571,542	248,000
Net increase/(decrease) in cash and cash equivalents	6,831,435	(221,000)
Cash and cash equivalents at the beginning of the year	1,617,000	2,030,000
Effects of exchange rate changes on cash and cash equivalents	30,492	(192,000)
Cash and cash equivalents at the end of the period	8,478,927	1,617,000

The accompanying notes form part of these financial statements.

Notes to the Financial Statements

Note 1 - Statement of Significant Accounting Policies

Corporate Information

This Preliminary Financial Report covers the consolidated entity of Emefcy Group Limited and its controlled entities. The Company's principal activities are research, development and commercialisation of wastewater treatment solutions.

The Company's Preliminary Financial Report does not include all the notes of the type normally included in an Annual Financial Report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial report.

Basis of preparation

This Preliminary Financial Report has been prepared in accordance with the recognition and measurement requirements, but not all disclosure requirements, of Australian Accounting Standards and Interpretations and the Corporations Act 2001. Australian Accounting Standards include Australian equivalents to International Financial Reporting Standards.

The Preliminary Final Report has been prepared on an accruals basis and is based on historical costs. Cost is based on fair values of the consideration given in exchange for assets.

The presentation currency adopted in the preparation of the preliminary financial report is United States Dollars.

On 18 December 2015 Emefcy Group Limited (formerly Savcor Group Limited) completed the legal acquisition of Emefcy Limited (Israel). Under the Australian Accounting Standards Emefcy Limited (Israel) was deemed to be the accounting acquirer in this transaction. The acquisition has been accounted for as a reverse acquisition by which Emefcy Limited (Israel) acquired the net assets and listing status of Emefcy Group Limited.

Accordingly, the consolidated financial statements of the Emefcy Group Limited have been prepared as a continuation of the business and operations of Emefcy Limited (Israel). As the deemed acquirer, Emefcy Limited (Israel) has accounted for the acquisition of Emefcy Group Limited from 18 December 2015. The comparative information for the 12 months ended 31 December 2014 presented in the consolidated financial statements is that of Emefcy Limited (Israel) as presented in its last set of year-end financial statements.

The implications of the acquisition by Emefcy Limited on the financial statements are as follow:

Consolidated Statement of Profit or Loss and Other Comprehensive Income

- The 2015 Statement of Profit or Loss and Other Comprehensive Income comprises the total comprehensive income for the financial year, being the 12 months for the year ended 31 December 2015 for Emefcy Limited (Israel) and the period from 18 December 2015 until 31 December 2015 for Emefcy Group Limited.
- The 2014 Statement of Profit or Loss and Other Comprehensive Income comprises the full comparative financial year for Emefcy Limited (Israel) only.

Consolidated Statement of Financial Position

- The 2015 Statement of Financial Position as at 31 December 2015 represents the consolidated of Emefcy Limited (Israel) as the accounting acquirer and Emefcy Group Limited.
- The 2014 Statement of Financial Position represents Emefcy Limited (Israel) only as at 31 December 2014.

Consolidated Statement of Changes in Equity

The 2015 Statement of Changes in Equity comprises:

- The equity balance of Emefcy Limited (Israel) as at the beginning of the financial year (1 January 2015)
- The total comprehensive income for the financial year and transactions with equity holders, being the 12 months from Emefcy Limited (Israel) for the year ended 31 December 2015 and period from 18 December 2015 until 31 December 2015 for Emefcy Group Limited.
- The equity balance of the consolidated group comprising Emefcy Limited (Israel) and Emefcy Group Limited at the end of the financial year (31 December 2015)
- The 2014 Statement of Changes in Equity comprises the full financial year for Emefcy Limited (Israel) for the 12 months ended 31 December 2014.

Statement of Cash Flows

The 2015 Statement of Cash Flows comprises:

- The cash balance of Emefcy Limited (Israel) at the beginning of the financial year (1 January 2015)
- The transactions for the financial year for the 12 months of Emefcy Limited (Israel) ended 31 December 2015 and from 18 December 2015 until 31 December 2015 for Emefcy Group Limited.
- The cash balance of the consolidated entity comprising Emefcy Limited (Israel) and Emefcy Group Limited at the end of the period (31 December 2015).
- The 2014 Statement of Cash Flows comprises the full financial year of Emefcy Limited (Israel) for the year ended 31 December 2014.

Note 2 - Dividends

No dividends have been paid or declared by the Company since the beginning of the current reporting period. No dividends were paid for the previous reporting period.

Note 3 - Revenue

	Consolidated Entity	
	31 December 2015	31 December 2014
	US\$	US\$
Interest revenue	1,179	60,000
Total Operating Revenue	1,179	60,000

Notes to the Financial Statements *Continued.....*

Note 4 - Segment Information

Primary Reporting Format - Business Segments

The Company has identified its operating segments based on the internal reports that are reviewed and used by the management team in assessing performance and determining the allocation of resources.

The operating segments are identified by management based on the manner in which the expenses are incurred, and for the purpose of making decisions about resource allocation and performance assessment. Discrete financial information about each of these operating segments is reported by the executive management team to the board on a regular basis.

The consolidated entity's operating segments are Australia and Israel.

There is no comparative information as the Geographic Segment only commenced with the acquisition of Emefcy Group Limited on 18 December 2015.

31 December 2015		Australia US\$	Israel US\$	Total US\$
Segment Revenue				
Interest revenue		1,179	-	1,179
Total Revenue		1,179	-	1,179
Segment Expenses				
Segment depreciation expenses		-	(70,922)	(70,922)
Segment expenses		(285,944)	(741,381)	(1,027,325)
Unallocated expenses	(a)	-	-	(7,991,433)
Total Expenses		(285,944)	(812,303)	(9,089,680)
Income Tax Expense		-	-	-
Net Result		(284,765)	(812,303)	(9,088,501)
Assets				
Segment assets		8,125,788	3,965,532	12,091,320
Total Assets		8,125,788	3,965,532	12,091,320
Liabilities				
Segment liabilities		(155,546)	(1,573,718)	(1,729,264)
Unallocated liabilities	(b)	-	-	(1,000,000)
Total Liabilities		(155,546)	(1,573,718)	(2,729,264)

Notes to the Financial Statements *Continued.....*

Note 4 - Segment Information (Continued)

	Consolidated Entity
	31 December 2015
	US\$
<u>(a) Unallocated Expenses</u>	
Listing Expense Recognised on Reverse Acquisition	(5,801,624)
Cash consideration of acquisition	(2,000,000)
Other expenses	(189,809)
Total unallocated operating revenue	(7,991,433)
<u>(b) Unallocated Liabilities</u>	
Other liabilities	(1,000,000)
Total unallocated liabilities	(1,000,000)

Note 5 - Loss per Share

	Consolidated Entity	
	31 December 2015	31 December 2014
	US\$	US\$
Basic loss per share	(0.08)	(0.03)
Diluted loss per share	(0.08)	(0.03)
a) Net loss used in the calculation of basic and diluted loss per share	(9,088,501)	(2,020,000)
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	112,627,416	60,019,035 ¹
c) Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. All the options on issue do not have the effect of diluting the loss per share therefore they have been excluded from the calculation of diluted loss per share.		

¹ The weighted average shares has been revised and reflects the weighted average total actual shares of Emefcy Limited (Israel) (the legal parent) in issue after the date of acquisition.

Notes to the Financial Statements *Continued.....*

Note 6 - Contributed Equity

		Consolidated Entity	
		31 December 2015	31 December 2014
		US\$	US\$
Ordinary shares	(a)	28,325,226	12,597,640
Options	(b)	156,549	62,752
Total issued capital		28,481,775	12,660,392

(a) Ordinary Shares	Full year to 31 December 2015		Full year to 31 December 2014	
	No.	US\$	No.	US\$
Balance at the beginning of the period	4,324,138	12,597,640	4,324,138	12,586,640
Elimination of issued capital in Emefcy	(4,324,138)	-	-	-
Capital raising - Emefcy Limited (Israel)	-	797,079	-	-
Savcor issued capital at pre-acquisition	42,671,357	-	-	-
Deemed fair value of consideration to Savcor shareholders on Reverse Acquisition	-	6,077,632	-	-
Shares issued to Emefcy Limited (Israel) vendors on Reverse Acquisition	65,000,000	-	-	-
Issue of shares AU\$0.02 pursuant to the Prospectus	69,066,053	9,836,997	-	-
Shares issued to consultants during the period	700,000	99,700	-	-
Share-based compensation	-	-	-	11,000
Transaction costs relating to share issues		(1,083,822)		-
Balance at the end of the period	177,687,410	28,325,226	4,324,138	12,597,640
Deferred Consideration Shares to be issued ¹	22,500,000	-	-	-
Balance at the end of the period including deferred shares	199,937,410	28,325,226	4,324,138	12,597,640

¹The deferred consideration shares relate to the obligation for the Company to issue a further 22,500,000 shares to Emefcy Limited (Israel) vendors upon the satisfaction of the first milestone that a module of the SABRE (Spiral Aerobic Biofilm Reactor) has been delivered to the first customer's site on, or before 18 June 2016. As at 31 December 2015, the Directors are satisfied that the first milestone will be achieved in the next few months.

(b) Options	Full year to 31 December 2015		Full year to 31 December 2014	
	No.	US\$	No.	US\$
Balance at the beginning of the period	-	62,752	-	62,752
Unlisted Options issued in Emefcy	-	3,175	-	-
Unlisted Options issued in Savcor	8,213,644	-	-	-
Unlisted Options issued to Directors pursuant to the Prospectus	5,000,000	90,622	-	-
Balance at the end of the period	13,213,644	156,549	-	62,752

Note 7 - Commitments and Contingent Liabilities

As part of the consideration of the acquisition of Emefcy, the Company has an obligation to issue a further 22,500,000 shares to Emefcy Limited (Israel) vendors upon, and subject to, the satisfaction of the second milestone. The milestone pursuant to the Term Sheet is that Emefcy Limited (Israel) has entered into firm contractual engagements representing an aggregate US\$2 million (including all associated grants and incentives) on, or before 18 December 2017. As at 31 December 2015, the Directors deemed that the second milestone has not been met.

The Company also has an outstanding redeemable note with a face value of US\$ 1 million to one Emefcy vendor and is redeemable subject to the satisfaction of the milestone described above. It should be noted however that the actual cash payment is not due until the earlier of 18 June 2018 or a subsequent capital raising being successfully completed.

Other than the above, the economic entity has no other contingent liabilities or contingent assets as of 31 December 2015 and 31 December 2014. The economic entity has no commitments as of 31 December 2015 and 31 December 2014.

Note 8 - Events Subsequent to Reporting Date

No matters or circumstances have arisen since the end of the reporting period which significantly affected or may significantly affect the operations of the economic entity, the result of those operations or the state of affairs of the economic entity in subsequent financial years.

Note 9 - Audit

These accounts are currently in the process of being audited. An Annual Report for the year ended 31 December 2015 containing the Audit Report shall be provided in due course.

Corporate Directory

DIRECTORS

Mr Richard Irving	Executive Chairman
Mr Ross Haghighat	Non-Executive Director
Mr Peter Marks	Non-Executive Director
Mr Phillip Hains	Non-Executive Director and Joint Company Secretary
Mr Eytan Levy	Managing Director

COMPANY SECRETARIES

Mr Ross Kennedy
Mr Phillip Hains

COMPANY

Emefcy Group Limited
ABN 52 127 734 196

WEBSITE

www.emefcy.com

PRINCIPAL PLACE OF BUSINESS

7 Ha'eshel st, Caesarea Industrial Park,
P.O. Box 3171 , 30889
Israel
Phone: +972 4 6277555
Fax: +972 4 6277556

REGISTERED OFFICE

Suite 1, 1233 High Street
Armadale, VIC, 3143, Australia
Phone: +61 (0)3 9824 5254
Fax: +61 (0)3 9822 7735

SHARE REGISTRY

Boardroom Pty Ltd
Level 12, 225 George Street
Sydney, NSW, 2000, Australia

Telephone: 1300 737 760 (local)
+61 2 9290 9600 (international)

SOLICITORS

Quinert Rodda & Associates Pty Ltd

Level 6, 50 Queen Street
Melbourne, VIC, 3000, Australia

AUDITORS

BDO East Coast Partnership
Level 14, 140 William Street,
Melbourne VIC 3000
Australia

BANKER

National Australia Bank (NAB)
Melbourne, Victoria,
Australia

SECURITIES QUOTED

Australian Securities Exchange
- Ordinary Fully Paid Shares (Code: EMC)